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Abstract
Background: The aim of this study was to compare the 5-year survival and success rates of 3.3 mm dental
implants either made from titanium-zirconium (TiZr) alloy or from Grade IV titanium (Ti Grade IV) in mandibular
implant-based removable overdentures.
Methods: The core study had a follow-up period of 36 months and was designed as a randomized, controlled,
double-blind, split-mouth multicenter clinical trial. Patients with edentulous mandibles received two Straumann
Bone Level implants (diameter 3.3 mm, SLActive®), one of TiZr (test) and one of Ti Grade IV (control), in the
interforaminal region. This follow-up study recruited patients from the core study and evaluated the plaque and
sulcus bleeding indices, radiographic crestal bone level, as well as implant survival and success 60 months after
implant placement.
Results: Of the 91 patients who initially received implants, 75 completed the 36 month follow-up and 49 were
available for the 60 month examination. Two patients were excluded so that a total of 47 patients with an average
age of 72 ± 8 years were analysed. The characteristics and 36-month performance of the present study cohort did
not differ from the non-included initial participants (p > 0.05). In the period since the 36-month follow-up
examination, no implant was lost. The cumulative implant survival rate was 98.9 % for the TiZr group and 97.8 % for
the Ti Grade IV group. Crestal bone level changes at 60 months were not different in the test and control group
(TiZr −0.60 ± 0.69 mm and Ti Grade IV −0.61 ± 0.83 mm; p = 0.96). The cumulative implant success rate after
60 months was 95.8 and 92.6 % for TiZr and Ti Grade IV, respectively.
Conclusions: After 60 months, the positive outcomes of the 36 month results for TiZr and Ti Grade IV implants
were confirmed, with no significant differences with regard to crestal bone level change, clinical parameters and
survival or success rates. TiZr implants performed equally well compared to conventional Ti Grade IV 3.3 mm
diameter-reduced implants for mandibular removable overdentures.
Trial registration: Registered on www.clinicaltrials.gov: NCT01878331
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Background
Despite the progress in restorative techniques and pre-
ventive measures, tooth loss has still a high prevalence
in the older population, yet tends to occur later in life
[1–3]. This presents the dental profession with more
edentulous patients, where physiological ageing and
multimorbidity often dominate the dental treatment
planning [4]. Age-adequate treatment planning requires
easy to manage and reversible treatment concepts which
take into consideration a reduced hand grip strength,
dexterity, vision and tactile sensitivity of the patient. Pro-
spective planning is required in view of a potential
future functional decline which may render the patient
dependent for the activities of daily living. The implant
mandibular overdenture with two interforaminal im-
plants presents a multitude of functional and psycho-
social improvements for the edentulous patient when
compared to a conventional complete denture, which
often falls short in fully restoring impaired oral function
after tooth loss [5, 6]. Encouraged by long-term success
of implant-overdentures, the indications of endosseous
implants are more extended to clinically challenging sit-
uations in terms of available bone volume for implant
anchorage as well as compromised general health condi-
tions [7, 8]. Progress in the implant surfaces have allowed
for shorter healing times and improved osseointegration
[9]. New alloys have been developed with improved mech-
anical properties which allow diameter-reduced implants
being inserted even in clinically unfavourable anatomical
conditions and thus further extend the indications for
implant restorations [10]. It is important that implants are
designed to have the possibility for a “back-off” strategy if
a less retentive and sophisticated restoration is needed in
end of life care. In this aspect, two-piece implants present
the advantage that the abutment can be removed and ex-
changed for a lower retention abutment or even a healing
cap when functional decline renders denture management
or denture wearing difficult. As neuroplasticity is dimin-
ished in old age, treatment planning includes avoiding
comprehensive changes of dental restorations in very old
age, thus preferring versatile and transformable prostho-
dontic restorations.
Titanium is considered the “gold standard” for dental
implants due to its corrosion resistance and biocompati-
bility [11], but titanium alloys containing zirconium show
even better tensile and fatigue strength than pure titanium
[12]. For increasing the strength for small-diameter two-
piece implants, titanium-zirconium (TiZr) alloy (Roxolid®;
Institut Straumann AG, Basel, Switzerland) implants
with the SLActive® surface have been introduced.
36 months non-inferiority of Roxolid® implants was re-
ported for mandibular overdentures in a multi-center
RCT [13, 14]. The present study aims to confirm the
safety and long term clinical performance in terms of
crestal bone level change, physical stability and peri-
implant health of Roxolid® implants after 60 months in
the previously reported patient cohort provided with
two-implant-based overdentures.
Methods
This study was designed as prospective 5 to 10 years
follow-up of a randomized, controlled, double-blind, split-
mouth, multi-centre clinical trial that came to its end after
36 months (core study). The materials and methods of the
core study have been published previously [13, 14] and
will be briefly summarized here. The core study has been
conducted at eight sites in five countries (Belgium,
Germany, Italy, the Netherlands and Switzerland). The
follow-up study was conducted at 6 sites in 4 countries
(Belgium, Germany, Italy and Switzerland). The study was
performed in accordance with the Declaration of Helsinki
and Good Clinical Practice (ISO 14155:2011) and ap-
proved by the Independent Ethics Committees of the co-
ordinating investigator and all study sites. All participating
patients gave their written informed consent. The study
was registered at www.clinicaltrials.gov (registration no.
NCT01878331 [15]).
Patients and implants
Patients who had completed the core study were invited
to participate in the follow-up study to collect long-term
data, 5 and 10 years after implant placement. The pa-
tients were selected according to predefined inclusion
and exclusion criteria. The inclusion criteria were:
 Treatment in the core study,
 completed 36 month visit of the core study,
 informed and written consent and
 commitment to participate in the study over the
entire study duration.
The exclusion criteria were:
 Physical handicaps interfering with the ability to
perform adequate oral hygiene,
 failure to attend follow-up visits and
 use of any investigational drug or device during the
study period.
During the core study the patients were selected ac-
cording to predefined inclusion and exclusion criteria.
The inclusion criteria were: edentulous mandible, age
≥18 years, last tooth extraction >8 weeks prior to sur-
gery, sufficient bone height of at least 9 mm and bone
width for a 3.3 mm diameter implant installation with-
out simultaneous bone augmentation, as well as an
edentulous opposing dentition with an implant born or
conventional denture or a natural or restored dentition.
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The exclusion criteria essentially referred to various
medical conditions and can be consulted in the first
publication of the core study [13]. All patients had pre-
sented with an edentulous mandible and had received
two Straumann Bone Level implants (Institut Straumann
AG, Basel, Switzerland) in the interforaminal region,
randomly allocated to one side in a double-blind, split-
mouth design. Both implants had exactly the same de-
sign with a diameter of 3.3 mm and a SLActive surface,
the test implant was fabricated from titanium-zirconium
(TiZr) and the control implant from Grade IV titanium
(Ti Grade IV).
Clinical procedure
In the core study, surgery had been performed under
local anaesthesia following a standard surgical proced-
ure. Implants of 8, 10, 12 and 14 mm length had been
inserted and healing abutments had been installed to
allow for trans-mucosal healing. Sutures had been re-
moved 1 to 2 weeks after surgery and the healing abut-
ments had been replaced by Locator abutments (Zest
Anchors LLC, Escondido, CA, USA) 6 to 8 weeks after
implant placement. Within two weeks following abut-
ment connection the removable dentures were relined to
incorporate the female Locator parts. No metal frame-
work was placed. The patients had attended follow-up
visits at 6, 12, 24 and 36 months. Patients from 6 centres
who consented for the follow-up study were recalled for
the 60 month clinical visit. An additional follow-up is
planned for 10 years after implant placement.
Implant survival and success
Implants still in place 60 months after surgery were
counted as surviving implants. Adapted from the Buser
criteria, implant success was defined as follows: The
possibility for restoration, the absence of persistent pa-
tient complaints (pain, foreign body sensation and/or
dysesthesia), the absence of recurrent peri-implant infec-
tion with suppuration, the absence of implant mobility
and the absence of continuous radiolucency around the
implant [16].
Peri-implant bone level
Standardized panoramic radiographs had been taken at
baseline and 6, 12, 24, 36 and 60 months after implant
placement (Fig. 1). Film-based images were digitized via
video camera, light box and image analysis program
[17, 18] and digital images were analyzed using ImageJ
1.33 open software (National Institutes of Health, Bethesda,
MD, USA). The analysis of all images was performed by an
independent expert.
The known implant length had been used as reference
for the analysis. The reference line for the bone level
measurements was the implant chamfer 0.2 mm above
the implant shoulder. The bone level was defined as dis-
tance between the reference point and the first bone-to-
implant contact (Fig. 2). The mean value from mesial
and distal measurements was used for the evaluation.
The bone level change was calculated as a function of
the baseline level at implant placement.
Soft tissue assessment
Soft tissue assessment had been performed at prosthesis
placement and 6, 12, 24, 36 and 60 months after implant
placement by calibrated operators. Modified Plaque Index
(mPI) and the modified Sulcus Bleeding Index (mSBI) ac-
cording to Mombelli were recorded for the lingual, buccal,
mesial and distal sites of the implant [19].
Safety assessment
Patient safety evaluation included reporting of complica-
tions, adverse events (AEs), serious adverse events (SAEs)
and device deficiencies. AEs and SAEs were assessed for
their relation to the study device and severity.
Statistical analysis
Efficacy analysis was performed for crestal bone level
change, implant survival and success and soft tissue pa-
rameters up to 60 months after implant placement based
on the “per protocol” (PP) data set. Comparisons be-
tween the test and the control group were based on the
corresponding 95 % confidence intervals. Changes in
crestal bone levels have been compared by t-tests be-
tween the treatment groups, the p-values are of descrip-
tive nature. Continuous data are presented as mean
Fig. 1 Radiograph showing test and control implant in the interforaminal region. The analysis was performed by an independent investigator
using ImageJ software
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values (± standard deviation, SD). For the analysis of
crestal bone level changes presented here missing data
were not imputed. Differences in the mPI and the mSBI
were evaluated by the Wilcoxon Rank Sum test. Kaplan-
Meier analysis was used to evaluate implant success and
survival and the distributions were compared by log-
rank tests. The “safety data” encloses all enrolled pa-
tients, who received a study device during the core
study. The “intention to treat” (ITT) population com-
prises all enrolled subjects regardless of any protocol
deviation and/or premature termination. The PP popu-
lation comprises all enrolled patients in whom no
major protocol deviation was observed.
Results
Patients
Ninety-one patients were enrolled in the core study and
75 patients completed the 36 month visit. During this
period, 11 patients were lost to follow up, one withdrew
consent, one had an adverse event unrelated to the study
treatment and three study participants died. Following
the 36 month examination, 26 patients were either lost
for follow-up or were not eligible for various reasons:
One patient was the only patient treated in one centre
and it seemed unreasonable to request ethical permis-
sion. Another centre did not receive the clearance from
the Ethics Committee for the continuation of the study
in time; hence further nine patients were not eligible for
participation. Finally, 49 patients from the core study
were available at the 60 month visit and consented to
participate in the follow-up study (Fig. 3). The patient
recruitment for the follow-up period started in June
2013 and the last 60 month visit was performed in
January 2014.
All 49 patients were eligible for the safety evaluation.
One patient was excluded from the ITT population be-
cause of unknown implant allocation during the core
study (n = 48, ITT population). Furthermore, one patient
could not be analysed according to the PP population,
because one of the two implants was lost and replaced
during the core study (n = 47, PP population). For many
patients time window deviations were observed and cat-
egorized as “minor protocol deviations”without further
consequences for the data analysis.
The mean age of the PP population was 72 ± 8 years at
the 60 month follow-up (range 54 – 92 years). The pa-
tient demographic data are presented in Table 1. The
majority of patients (87.2 %) suffered from clinically rele-
vant diseases; among the most frequent ones were
hypertension and hyperlipidaemia.
The primary efficacy variable is implant survival
assessed 10 years after implant placement, but the study
design includes the assessment of various secondary pa-
rameters after 5 and 10 years.
Implant survival and success
During the observation period of the follow-up study,
between 36 and 60 months after implant placement, no
implants were lost. However, three implants had been
lost during the core study within the first 12 months
after implant placement, one in the test group (TiZr)
and two in the control group (Ti Grade IV). Kaplan-
Fig. 2 Illustration of the bone level measurements. (1) Chamfer to first implant-to-bone contact, mesial (2) Chamfer to first implant-to-bone contact,
distal (3) Length of implant
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Meier curves show that the probability of implant sur-
vival is declining to 98.9 % for the TiZr group and to
97.8 % for the Ti Grade IV group within the first year
after implant placement and remains stable at this level
for up to 60 months. There were no significant differ-
ences between the two groups (p = 0.56). Considering
the 26 patients, who were either “lost to follow-up” after
completion of the core study or not eligible for
participation, as failures, a worst case scenario would re-
sult in an implant survival of 53.8 %.
During the core study one implant of each, the test
and the control group had been classified as “not suc-
cessful” due to peri-implant infection and suppuration.
In addition, at the 60 month visit one patient showed a
peri-implant infection around the TiZr implant. Further,
two Ti Grade IV implants were considered not success-
ful due to continuous radiolucency around the implants.
Therefore, the cumulative implant success rates (Fig. 4)
were 95.8 % and 92.6 % for TiZr and Ti Grade IV, re-
spectively (Kaplan Meier curves; failed implants were
also counted as “not successful”; p = 0.47).
Bone level change
There were no significant differences in crestal bone
level changes between the TiZr and the Ti Grade IV
group, assessed 60 months after implant placement (p =
0.96). The mean change in the TiZr group was −0.60 ±
0.69 mm and in the Ti Grade IV group −0.61 ± 0.83 mm,
ranging from −3.57 to 0.16 mm and from −3.65 to
0.44 mm, respectively. The majority of implant sites
showed crestal bone loss between 0 and 1.0 mm or
crestal bone gain (Fig. 5). Crestal bone level changes
were more pronounced in the first years after implant
Fig. 3 Patient flow diagram for the core- (0 – 36 months) and the follow-up study (up to 60 months)
Table 1 Demographic data of the study population
Number Percent
Gender
Male 24 51.1
Female 23 48.9
Smoking status
Non-smoker 31 66.0
Past-smokera 16 34.0
Current clinically relevant disease
Yesb 41 87.2
No 6 12.8
Demographic patient data, 60 months after implant placement (PP population,
n = 47). a i.e. > 10 cigarettes/day; b most frequently hypertension
and hypercholesterolemia
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Fig. 4 Kaplan-Meier analysis of implant survival and success. a Implant survival and b success from implant placement to 60 months. Patients lost
to follow-up during or after completion of the core study (0–36 months) were censored. Scaling of the Y-axes 0.92 to 1.00
Fig. 5 Categorized changes in peri-implant bone level 60 months after implant placement. Implants were categorized according to crestal bone
level change (PP population, n = 47, some radiographs were impossible to analyse)
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placement (Fig. 6). A sensitivity analysis was performed
for the core study (12, 24 and 36 months) confirming
that there were no significant differences between the
original patient population and the population of this
follow-up study with regard to crestal bone level changes
(p = 0.44, 0.41 and 0.61 (Ti Grade IV), respectively p =
0.29, 0.35, 0.28 (TiZr), respectively).
Soft tissue and safety assessments
After 60 months no significant differences in mPI and
mSBI were determined between the patients of the TiZr
and the Ti Grade IV group (p = 0.23 and p = 0.77, re-
spectively). Most of the patients showed an mPI score 0
or 1 and the same results were observed for the mSBI
(Table 2).
Four of the 49 patients (8.2 %) experienced an AE dur-
ing the observational period from 36 to 60 months. In
accordance with the assessment of implant success, two
patients presented with radiolucency around the implant
and one patient with peri-implant infection, classified as
AEs related to the study device. Another AE, a denture
related ulcer, was not related to the implant. None of the
patients experienced an SAE between 36 and 60 months
after implant placement.
Discussion
This study was designed as a prospective, randomized,
double-blind and split-mouth clinical trial, where dental
implants made of TiZr alloy were compared to implants
made of Ti Grade IV. Both types of implants had a SLAc-
tive surface. After an observation period of 60 months, no
significant differences in crestal bone level change, clinical
parameters or survival and success rates were found be-
tween the groups. The outcomes seen at 12 as well as
36 months continued until 60 months, indicating that
TiZr implants in this clinical setting were comparable to
Ti Grade IV implants.
Long-term observations are highly relevant when
recommending a medical device for clinical use, even
more so for elderly patients, where prosthodontic resto-
rations should be designed for long-term survival, as
renewal of prostheses might become difficult with in-
creasing frailty and multimorbidity. Adjustments which
may become necessary to adapt the prosthodontic restor-
ation to functional decline should rather be performed by
a simple alteration of the denture to minimize the chal-
lenges to an elderly person’s neuroplasticity and capacity
of adaptation. Complications or failures in late life can be
minimized when using only well documented and high
quality materials for dental restorations. Biological compli-
cations may still occur, as the overall risk of implant fail-
ure seems influenced by biological parameters like history
of periodontal disease or residual periodontal pockets
[20–22]. Patient behaviour such as smoking [23, 24] un-
favourable oral hygiene [25] or the absence of an adequate
peri-implant width of keratinized and attached mucosa
[26, 27] may also play a role. Technical aspects such as
implant design and surface may also largely vary the clin-
ical outcome, as was recently demonstrated in a large-
scale industry independent study on implant survival [28].
In this study the mentioned risk factors were con-
firmed, and in addition, implant length and implant
brand were identified as relevant factors for implant
survival and success.
The present data confirm that Roxolid® implants were
comparable to the traditional Grade IV titanium alloy in
3.3 mm diameter implants for an implant-supported
mandibular overdenture over a 60 months period. This
confirmation is of particular importance with regard to
the above mentioned concern about safety and quality of
implant materials in pre-elderly and elderly patients.
The peri-implant bone loss, modified Plaque Index,
modified Sulcus Bleeding Index as well as implant suc-
cess and survival are not statistically different between
the two implant materials. One of the strengths of this
study is the split-mouth design, which provides an iden-
tical biological environment to the test and control im-
plant. Another strength is the use of 3.3 mm diameter
implants in a region, where the bone volume might
Fig. 6 Bone level changes from implant placement to 60 months.
Mean peri-implant bone level change up to 60 months (PP population,
n = 47, some radiographs were impossible to analyse). Positive values:
crestal bone level decrease. Negative values: crestal bone level increase.
Missing values were excluded from the analysis
Table 2 Plaque index and sulcus bleeding indices after
60 months
Plaque Index (mPI) Sulcus Bleeding Index (mSBI)
TiZr % Ti Grade IV % TiZr % Ti Grade IV %
Score 0 59.6 68.6 66.5 68.6
Score 1 15.4 16.0 17.0 20.2
Score 2 16.5 8.5 13.8 10.1
Score 3 8.5 7.4 2.7 1.1
Modified Plaque Index and modified Sulcus Bleeding Index according to
Mombelli et al. [19], 60 months after implant placement (p = 0,23 (mPI), p = 0.77
(mSBI), PP population, n = 47)
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often, but not always be available for larger diameter im-
plants. Even the right- or left handedness of a patient or
the preferred chewing side may not have influenced the
results, as the side-attribution of the test and control
group was randomized. However, any clinical study has
inherent inconsistencies, as one patient may vary from
the other in a multitude of aspects. A further substantial
shortcoming is that not all of the 92 patients who origin-
ally received implants were available for all follow-up
visits. The core study was planned for 36 months, and
ethical permission and insurance had expired after this
follow-up period and renewal was necessary. One centre
had only one participant recruited, and it seemed unrea-
sonable to undergo the effort of study submission to the
Ethics Committee for this single case. A further centre
did not obtain ethical approval in time. A total of 26 pa-
tients was lost for recruitment for the present study. A
worst-case survival rate was therefore calculated at
53.8 %. However, knowing that 10 patients were not in-
cluded for formal reasons, and taking into account that
the included patients did not differ statistically from the
not-included participants from the core study at baseline
as well as at 12, 24 and 36 month follow-up, it seems
reasonable to assume that this worst-case scenario is un-
realistic. The crestal bone level changes reported in the
present study are within the range reported in the litera-
ture for similar clinical indications. A recent meta-analysis
on marginal bone level changes at dental implants after an
observation period of 60 months concludes that the an-
nual bone loss is below or much below what hitherto has
been reported [29]. The marginal bone loss noted in the
present patient cohort after 60 months was −0.60 ±
0.69 mm for the TiZr group and −0.61 ± 0.83 mm in the
Ti Grade IV group, respectively. The reported bone level
changes after 60 months are in between the one reported
by Laurell end Lundgren for the Straumann Dental Im-
plant System (0.48 mm (95 % CI −0.598, −0.360) and
the Brånemark System with 0.75 mm (95 % CI −0.802,
−0.693). When comparing these results with the ones
from the meta-analysis, one has to keep in mind that
both, elderly and edentulous patients are at particular
risk for reduced oral hygiene measures. Around one
third of this study’s patient cohort did present with
modified Plaque Index and modified Sulcus Bleeding
Index scores above zero. However, little is known on
the impact of biofilm on the peri-implant bone level
[30], especially for elderly patients with an aged im-
mune system. The relation between peri-implantitis
and oral hygiene will be of increasing importance for
the dental profession, as a growing number of patients
with implants will age, hence poor oral hygiene seems
pre-programmed.
The benefits of implant overdentures for edentulous pa-
tients are well documented and the cost-effectiveness of
this treatment protocol has been demonstrated [5, 6, 31].
Compared to conventional dentures, the chewing effi-
ciency may be significantly improved, given that new
implant-supported removable overdentures are manufac-
tured [32]. The chewing muscles seem more trained due
to the improved chewing performance and after stabilizing
a lower denture by means of implants the muscle bulk can
be re-gained, even in very old adults [33, 34]. A similar ef-
fect of training and re-training was shown also for the leg
muscles in a geriatric context [35]. Further improvements
of overdentures compared to conventional complete
dentures comprise denture satisfaction and Oral Health
Related Quality of Life [36], although these outcome
measures are complex and may vary between cultures
and personalities [37]. Elderly persons are in general
less demanding concerning an improvement of their
denture performance [38, 39], yet do in general appre-
ciate an improvement of their chewing performance
[40–42]. Nevertheless, around one third of edentulous
patients reject implant insertion because they object
the surgical intervention [43]. Low-diameter implants
may not only have a positive effect on the preservation
of the residual alveolar ridge and therefore be biologic-
ally favourable in certain clinical situations. They may
also avoid invasive bone augmentation procedures [44]
whereby patient’s morbidity as well as treatment costs
and time can be reduced significantly [10] and the
smaller the intervention, the more likely is the accept-
ance in edentulous patients.
Conclusion
In conclusion it can be stated that the TiZr alloy (Roxolid®)
implants provide a long-term safe and reliable alternative to
the available portfolio of dental implants, traditionally man-
ufactured from Ti Grade IV. The improved mechanical
properties of TiZr may extend the indications in implant
therapy to more challenging clinical situations and allow
promoting a minimal invasive treatment approach which is
particularly suitable for elderly patients.
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